Pharmaceutical evaluation of glibenclamide products available in the Jordanian market

®) which was obtained from the Saudi market was subjected to analysis and used as a reference product. All products were found satisfactory in terms of identification and related substances as per the BP requirements. However, the assay results showed that only two products, in addition to the reference (Daonil ® ) satisfied the BP specifications which required glibenclamide content to be within the range: 95 to 105% of the labeled content. All products, in spite of marginal deviations for two of them, were found to pass the United States Pharmacopoeia (USP) assay specifications (90 to 110%). Significant differences in dissolution behavior were observed between the different generics and the originator (Daonil ® ). Daonil ® exhibited the lowest dissolution profile while some products showed

[1]  C. Anyakora,et al.  Quality survey of some brands of artesunate- amodiaquine in Lagos drug market , 2012 .

[2]  Gert Storm,et al.  The therapeutic equivalence of complex drugs. , 2011, Regulatory toxicology and pharmacology : RTP.

[3]  L. Beauclair,et al.  Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching. , 2010, International clinical psychopharmacology.

[4]  I. M. Arhewoh,et al.  In-vitro evaluation of the pharmaceutical quality of some ibuprofen tablets dispensed in Nigeria , 2009 .

[5]  S. Taddei,et al.  Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers. , 2009, British journal of clinical pharmacology.

[6]  F. Pattarino,et al.  Difficulties in the Production of Identical Drug Products from a Pharmaceutical Technology Viewpoint , 2008, Drugs in R&D.

[7]  J. Vial,et al.  Pharmaceutical quality of docetaxel generics versus originator drug product: a comparative analysis. , 2008, Current medical research and opinion.

[8]  Julian C. Smith,et al.  Are generic formulations of carvedilol of inferior pharmaceutical quality compared with the branded formulation?* , 2006, Current medical research and opinion.

[9]  N. Najib,et al.  In Vitro and In Vivo Evaluation of Glibenclamide in Solid Dispersion Systems , 2004, Drug development and industrial pharmacy.

[10]  Raimar Löbenberg,et al.  Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Dissolution Behavior of Glibenclamide , 2000, Pharmaceutical Research.

[11]  Christos Reppas,et al.  Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms , 2004, Pharmaceutical Research.

[12]  S. Epstein,et al.  Disintegration/dissolution profiles of copies of Fosamax (alendronate) , 2003, Current medical research and opinion.

[13]  J. Dressman,et al.  The BCS: Where Do We Go from Here? , 2001 .

[14]  M. Green,et al.  A colorimetric field method to assess the authenticity of drugs sold as the antimalarial artesunate. , 2000, Journal of pharmaceutical and biomedical analysis.

[15]  L. Luzi,et al.  Glibenclamide: an old drug with a novel mechanism of action? , 1997, Acta Diabetologica.